Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00288769|
Recruitment Status : Completed
First Posted : February 8, 2006
Last Update Posted : January 23, 2009
Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids .
A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets.
Purpose of the research:
To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS).
Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Aphthous Stomatitis||Drug: daily sublingual tablets Vitamin B12 1000 mcg versus placebo||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Study Start Date :||March 2006|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||January 2008|
|2||Drug: daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00288769
|Ben-Gurion University of the Negev|
|Beer Sheva, Israel|
|Principal Investigator:||Ilia Volkov, MD||Ben-Gurion University of the Negev|